Scientists argue for more FDA oversight of health care AI tools

An agile, transparent, and ethics-driven oversight system is needed for the U.S. Food and Drug Administration (FDA) to balance innovation with patient safety when it comes to artificial intelligence-driven medical technologies. That is the takeaway from a new report issued to the FDA, published this week in the open-access journal PLOS Digital Health by Leo Celi of the Massachusetts Institute of Technology and colleagues.

This post was originally published on this site